Retatrutide vs Semaglutide
Comparison of the investigational triple agonist retatrutide to the established GLP-1 agonist semaglutide.
Last updated: January 28, 2026
Retatrutide
Semaglutide
Overview
Retatrutide is an investigational triple hormone receptor agonist (GLP-1/GIP/glucagon) in Phase 3 development by Eli Lilly. Semaglutide is an FDA-approved GLP-1 receptor agonist marketed as Ozempic/Wegovy. This comparison examines what Phase 2 data shows and key differences in mechanism.
Important: Retatrutide is not FDA-approved. This comparison is for educational purposes about ongoing research.
Key Facts
| Aspect | Retatrutide | Semaglutide |
|---|---|---|
| Status | Investigational (Phase 3) | FDA-approved |
| Mechanism | Triple agonist (GLP-1/GIP/glucagon) | Single agonist (GLP-1) |
| Developer | Eli Lilly | Novo Nordisk |
| Trade Names | None (investigational) | Ozempic, Wegovy, Rybelsus |
Mechanism Comparison
| Receptor | Retatrutide | Semaglutide |
|---|---|---|
| GLP-1 | Agonist | Agonist |
| GIP | Agonist | None |
| Glucagon | Agonist | None |
Triple Agonist Rationale
GLP-1 effects: Appetite reduction, insulin secretion, slowed gastric emptying
GIP effects: Enhanced insulin response, potential fat metabolism effects, may reduce GLP-1 side effects
Glucagon effects: Increased energy expenditure, hepatic lipid oxidation, thermogenesis
The hypothesis is that adding glucagon receptor activity may enhance energy expenditure and fat loss beyond what GLP-1/GIP dual agonism achieves.
Clinical Trial Evidence
Retatrutide Phase 2 (Published 2023)
The Phase 2 trial in obesity (N=338) tested multiple doses over 48 weeks:
| Dose | Weight Loss | Notable |
|---|---|---|
| 1mg | -8.7% | Lowest dose |
| 4mg | -17.1% | Mid-range |
| 8mg | -22.8% | Higher dose |
| 12mg | -24.2% | Highest dose tested |
| Placebo | -2.1% | Control |
Key findings:
- Highest dose showed ~24% weight loss at 48 weeks
- Weight loss appeared to still be trending downward at study end
- GI side effects were dose-dependent
Semaglutide (Wegovy) STEP Trials
| Trial | Duration | Weight Loss |
|---|---|---|
| STEP 1 | 68 weeks | -14.9% (vs -2.4% placebo) |
| STEP 3 | 68 weeks | -16.0% (vs -5.7% placebo) |
| STEP 5 | 104 weeks | -15.2% (vs -2.6% placebo) |
Important Trial Differences
| Factor | Retatrutide Phase 2 | Semaglutide STEP |
|---|---|---|
| Phase | 2 (dose-finding) | 3 (pivotal) |
| Sample Size | 338 | 1,000-2,000+ per trial |
| Duration | 48 weeks | 68-104 weeks |
| Population | Varied inclusion | Standardized obesity criteria |
Caution: Phase 2 results often don’t fully replicate in Phase 3. Direct comparison has significant limitations.
Safety Comparison
Retatrutide Phase 2 Side Effects
| Side Effect | Incidence |
|---|---|
| Nausea | 25-45% (dose-dependent) |
| Diarrhea | 15-25% |
| Vomiting | 10-20% |
| Decreased appetite | 15-25% |
| Constipation | 5-15% |
Semaglutide (Post-marketing) Side Effects
| Side Effect | Incidence |
|---|---|
| Nausea | 20-44% |
| Diarrhea | 20-30% |
| Vomiting | 15-25% |
| Constipation | 15-25% |
| Abdominal pain | 15-20% |
Glucagon-Related Considerations
Retatrutide’s glucagon activity raises theoretical considerations:
- Increased heart rate (observed in trials)
- Potential hepatic effects
- Long-term cardiovascular effects unknown
- Blood glucose effects in diabetes (complex)
Metabolic Effects Beyond Weight
Retatrutide Phase 2 Data
| Metric | Change at 12mg |
|---|---|
| Fat mass reduction | -39% (DEXA) |
| Lean mass | Relatively preserved |
| Liver fat | -81% reduction |
| A1C (in T2D subset) | -2.0% |
Semaglutide Effects
| Metric | Typical Changes |
|---|---|
| Fat mass reduction | Variable |
| Liver fat | Reduced (NAFLD studies) |
| A1C (in T2D) | -1.0 to -1.8% |
| Cardiovascular | 20% MACE reduction (SELECT) |
Development Status
Retatrutide Pipeline
| Indication | Phase | Status |
|---|---|---|
| Obesity | Phase 3 | TRIUMPH program ongoing |
| Type 2 Diabetes | Phase 3 | Ongoing |
| MASH/NASH | Phase 2 | Ongoing |
Semaglutide Availability
| Brand | Indication | Status |
|---|---|---|
| Ozempic | Type 2 diabetes | Approved |
| Wegovy | Obesity | Approved |
| Rybelsus | Type 2 diabetes (oral) | Approved |
Key Differences
| Factor | Retatrutide | Semaglutide |
|---|---|---|
| Approval | Not approved | FDA-approved since 2017 |
| Real-world data | None | Extensive |
| Cardiovascular data | None | SELECT trial positive |
| Mechanism complexity | Triple agonist | Single agonist |
| Long-term safety | Unknown | 7+ years of data |
| Efficacy in trials | Higher weight loss | Established |
Summary
-
Retatrutide: Investigational triple agonist with promising Phase 2 data showing potentially greater weight loss than existing drugs. Awaiting Phase 3 results. Not available outside clinical trials.
-
Semaglutide: Established, FDA-approved GLP-1 agonist with extensive real-world data, proven cardiovascular benefits (SELECT trial), and multiple formulations available.
Phase 2 data is encouraging but not definitive. Phase 3 trials will determine if retatrutide’s efficacy and safety profile supports FDA approval.
This comparison is for educational purposes only. Retatrutide is investigational and not available for prescription. Medication decisions should be made with a healthcare provider.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.